Clinical trials: Meningioma
Brain and Central Nervous System Tumors, Metastatic Cancer
A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more…
- Trial name
- NCT00784914
- Testing
- temsirolimus, pharmacological study, cytokine levels
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- City of Hope Medical Center
Meningioma
Information Presentation Formats
Prevention and early detection of medical problems can greatly reduce health care costs, yet time and again, people avoid or ignore services that could help detect medical problems early enough to prevent or reduce the severity…
- Trial name
- NCT02267928
- Testing
- Check Symptoms, Uncheck Symptoms, Experienced
- Where
- United States
- Volunteers
- 305 people, healthy volunteers welcome
- Sponsor
- Carnegie Mellon University
Childhood Burkitt Lymphoma, Childhood Central Nervous System Choriocarcinoma
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
This phase I trial is studying the side effects and best dose of vorinostat when given together with bortezomib in treating young patients with refractory or recurrent solid tumors, including CNS tumors and lymphoma.
- Conditions
- Childhood Burkitt Lymphoma, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous System Germinoma
- Trial name
- NCT00994500
- Testing
- vorinostat, bortezomib, pharmacological study
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Kidney Cancer
Early Enteral Tube Feedings in Children Receiving Chemo for AML/MDS & High Risk Solid Tumors
RATIONALE: Tubefeeding may help maintain good nutrition and lessen weight loss in younger patients receiving chemotherapy for cancer.
- Conditions
- Brain and Central Nervous System Tumors, Kidney Cancer, Leukemia, Liver Cancer
- Trial name
- NCT00624962
- Testing
- nutritional intervention, therapeutic nutritional supplementation
- Sponsor
- Vanderbilt University
Anaplastic (Malignant) Meningioma, Atypical Meningioma
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
The purpose of this research study is to determine the effects bevacizumab (the study drug) combined with Optune (the study device) tumor treatment field therapy has on meningiomas.
- Conditions
- Anaplastic (Malignant) Meningioma, Atypical Meningioma, Grade II Meningioma, Grade III Meningioma
- Trial name
- NCT02847559
- Testing
- Bevacizumab, Electric Field Therapy, NovoTTF-200A Device
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Northwestern University
Meningeoma, Thrombembolism
Meningioma and Embolism Thrombosis Risk & Investigation of Coagulation
Despite being generally benign tumors, meningiomas are associated with an increased risk for thrombembolic complications after surgical resection. The molecular mechanisms underlying this circumstance are still unknown.
- Conditions
- Meningeoma, Thrombembolism, Surgical Resection
- Trial name
- 001_2024_BO2 (NCT06709833)
- Where
- Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Meningioma
MEningioma Detection Using Non Contrast MRI TecHniquEs
Meningioma, an extra-axial brain tumor developed at the expense of meninges, accounts for 35% of central nervous system tumors, and its incidence is estimated at 3% in large autopsy series.
- Trial name
- MENTHE (NCT04113408)
- Testing
- FABIR sequence
- Where
- France
- Volunteers
- 315 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Meningioma Atypical
Multisession Radiosurgery in Residual/Recurrent Grade II Meningiomas.
Fractionated radiosurgery will be delivered to atypical meningioma lesions in salvage setting for patients who present post-surgical residual lesion or develop recurrence.
- Trial name
- ATM (NCT05081908)
- Testing
- Radiosurgery
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
High Grade Meningioma, Ependymoma
Rare CNS Tumors Outcomes &Risk
Background: Primary tumors of the brain and spine are those that start in the brain or spine. These tumors are rare, accounting for <2% of all cancers diagnosed in the United States.
- Conditions
- High Grade Meningioma, Ependymoma, Medulloblastoma, PNET
- Trial name
- NCT03251989
- Where
- United States
- Volunteers
- 326 people
- Sponsor
- National Cancer Institute (NCI)
Primary Brain Tumors, Diffuse Glioma
Proton Versus Photon Radiotherapy in Adults With Primary Brain Tumors
This study will be done in adults with brain tumors having good prognosis requiring treatment with radiotherapy. The current practice for brain radiotherapy involves treatment using X rays (photon radiotherapy).
- Conditions
- Primary Brain Tumors, Diffuse Glioma, Meningioma, Pituitary Adenoma
- Trial name
- PRIDE (NCT06831461)
- Testing
- Proton Beam Therapy, Photon Radiotherapy
- Where
- India
- Volunteers
- 156 people
- Sponsor
- Tata Memorial Centre
Acoustic Schwannoma, Adult Anaplastic Meningioma
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Acoustic Schwannoma, Adult Anaplastic Meningioma, Adult Ependymoma, Adult Grade I Meningioma
- Trial name
- NCT01125046
- Testing
- bevacizumab
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Northwestern University
Low Grade Glioma, Malignant Brain Glioma
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
This phase II trial tests the effect of decreasing (tapering) doses of dexamethasone on steroid side effects in patients after surgery to remove (craniotomy) a brain tumor.
- Conditions
- Low Grade Glioma, Malignant Brain Glioma, Malignant Brain Neoplasm, Meningioma
- Trial name
- NCT06132685
- Testing
- Biospecimen Collection, Computed Tomography, Dexamethasone
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Emory University
Glioblastoma, Cerebral Metastases
Impact of Salovum® and SPC® Flakes on Brain Tumor Induced Edema
The objective of this clinical trial is to explore the effects of Salovum®, an egg yolk powder enriched with the endogenous protein antisecretory factor, and SPC® flakes , hydrothermically processed oats, on cerebral edema with…
- Conditions
- Glioblastoma, Cerebral Metastases, Meningioma
- Trial name
- AFBTEdema (NCT06710249)
- Testing
- Salovum/SPC flakes
- Where
- Sweden
- Volunteers
- 20 people
- Sponsor
- Peter Siesjö
Recurrent High Grade Meningioma
Trabectedin for Recurrent Grade II/III Meningioma
The aim of this study is to collect data on activity, toxicity and quality of life of trabectedin therapy in patients with recurrent high-grade meningioma.
- Trial name
- NCT02234050
- Testing
- Trabectedin, Local standard of care
- Where
- 47 sites in Austria, Belgium and 8 more
- Volunteers
- 90 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Recurrent Meningioma
177Lu-DOTATATE for Recurrent Meningioma
Novel treatments are urgently needed for meningiomas progressing after local therapies (surgery, radiotherapy). So far, no effective systemic therapies are known in this situation.
- Trial name
- LUMEN-1 (NCT06326190)
- Testing
- Local standard of Care, 177Lu-DOTATATE
- Where
- 19 sites in Austria, France and 4 more
- Volunteers
- 136 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Neuroblastoma, Medulloblastoma
Molecular-Guided Therapy for Childhood Cancer
The purpose of this study is to test the feasibility (ability to be done) of experimental technologies to determine a tumor's molecular makeup.
- Conditions
- Neuroblastoma, Medulloblastoma, Glioma, Ependymoma
- Trial name
- NCT02162732
- Testing
- Guided Therapy
- Where
- 19 sites in United States, Lebanon
- Volunteers
- 186 people
- Sponsor
- Giselle Sholler
Brain Tumor, Recurrent, Brain Tumor
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
- Conditions
- Brain Tumor, Recurrent, Brain Tumor, Brain Tumor, Primary, Brain Tumor - Metastatic
- Trial name
- NCT04427384
- Testing
- GammaTile
- Where
- 54 sites in United States
- Volunteers
- 600 people
- Sponsor
- GT Medical Technologies, Inc.
Glioma, Malignant Brain Neoplasm
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
This phase I trial studies how well zirconium (Zr)-89 crefmirlimab berdoxam and immuno-positron emission tomography (PET) identifies areas of immune cell activity in patients with brain tumors that can be removed by surgery…
- Conditions
- Glioma, Malignant Brain Neoplasm, Meningioma, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT06650163
- Testing
- Advanced Magnetic Resonance Imaging, Brain Surgery, Electronic Health Record Review
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Meningioma, Radiation Toxicity
Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma:
For the purpose of this research, investigator will constitute several cohorts of patients, treated either by intensity-modulated radiotherapy, stereotactic radiotherapy or proton-therapy.
- Trial name
- CANCER-COG (NCT06036706)
- Testing
- Normo-fractionated intensity-modulated brain irradiation with or without stereotactic positioning, Hypo-fractionated stereotactic brain irradiation, Normo-fractionated proton therapy brain irradiation
- Where
- 3 sites in France
- Volunteers
- 108 people
- Sponsor
- Centre Francois Baclesse
Meningioma of Brain, Meningioma
Tumor Genomics, Individual Risk Factors, and External Drivers of Health on Health Outcomes for Patients With Meningioma
Meningiomas are the most common primary brain tumor, and some groups are diagnosed with higher-grade tumors and have clinically worse outcomes.
- Conditions
- Meningioma of Brain, Meningioma, Brain Tumor
- Trial name
- NCT07418775
- Testing
- Questionnaire, Medical Record Review
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco